References: 1. DUOBRII Lotion [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC. 2. Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287-293. 3. Kircik LH, Papp KA, Gold LS, Harris S, Lin T, Pillai R. Assessing the synergistic effect of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2019;18(3):279-284. 4. Sugarman JL, Gold LS, Lebwohl MG, et al. A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16(3):611-618. 5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659. 6. Data on file. 7. Bhatia N, Pariser D, Kircik L, et al. Safety and efficacy of a halobetasol 0.01%/tazarotene 0.045% fixed combination lotion in the treatment of moderate-to-severe plaque psoriasis: a comparison with halobetasol propionate 0.05% cream. J Clin Aesthet Dermatol. 2018;11(11):15-19.